4.7 Article

Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer

Journal

CANCER DISCOVERY
Volume 10, Issue 9, Pages 1312-1329

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-19-1493

Keywords

-

Categories

Funding

  1. Terry Fox Research Institute (New Frontiers Research Program) [PPG-1064]
  2. Canadian Cancer Research Society
  3. Ontario Institute for Cancer Research through Government of Ontario
  4. Canadian Institute for Health Research (CIHR) [136963, 158225, 363288]
  5. Princess Margaret Cancer Centre
  6. Princess Margaret Cancer Foundation
  7. Ontario Ministry of Health
  8. Reseau de Recherche en Cancer of the FRQS
  9. Quebec Breast Cancer Foundation
  10. Oncopole
  11. Gattuso-Slaight Personalized Cancer Medicine Fund at Princess Margaret Cancer Centre
  12. SU2C Canada -Canadian Cancer Society Breast Cancer Dream Team Research Funding [SU2C-AACR-DT-18-15]
  13. Government of Ontario
  14. CIHR
  15. Fonds de Recherche en Sante du Quebec (FRQS) postdoctoral research award
  16. Cancer Research Society Next-Generation of Scientists transition award
  17. Ontario Institute for Cancer Research
  18. CIHR New Investigator Award
  19. Bernard and Francine Dorval Award for Excellence from the Canadian Cancer Society
  20. Diane and Sal Guerra Chair in Cancer Genetics at McGill University
  21. CIHR fellowship
  22. Connaught International Scholarships
  23. FRQS
  24. AbbVie
  25. Bayer Pharma AG
  26. Boehringer Ingelheim
  27. Canada Foundation for Innovation
  28. Eshelman Institute for Innovation
  29. Genome Canada through Ontario Genomics Institute [OGI-055]
  30. Innovative Medicines Initiative (EU/EFPIA
  31. ULTRA-DD) [115766]
  32. Janssen
  33. Merck KGaA
  34. Darmstadt, Germany
  35. MSD
  36. Novartis Pharma AG
  37. Ontario Ministry of Research, Innovation and Science (MRIS)
  38. Pfizer
  39. Sao Paulo Research Foundation-FAPESP
  40. Takeda
  41. Wellcome

Ask authors/readers for more resources

Tumor progression upon treatment arises from preexisting resistant cancer cells and/or adaptation of persister cancer cells committing to an expansion phase. Here, we show that evasion from viral mimicry response allows the growth of taxane-resistant triple-negative breast cancer (TNBC). This is enabled by an epigenetic state adapted to taxane-induced metabolic stress, where DNA hypomethylation over loci enriched in transposable elements (TE) is compensated by large chromatin domains of H3K27me3 to warrant TE repression. This epigenetic state creates a vulnerability to epigenetic therapy against EZH2, the H3K27me3 methyltransferase, which alleviates TE repression in taxane-resistant TNBC, leading to double-stranded RNA production and growth inhibition through viral mimicry response. Collectively, our results illustrate how epigenetic states over TEs promote cancer progression under treatment and can inform about vulnerabilities to epigenetic therapy. SIGNIFICANCE Drug-resistant cancer cells represent a major barrier to remission for patients with cancer. Here we show that drug-induced metabolic perturbation and epigenetic states enable evasion from the viral mimicry response induced by chemotherapy in TNBC. These epigenetic states define a vulnerability to epigenetic therapy using EZH2 inhibitors in taxane-resistant TNBC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available